secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K
Filed at:   2024-08-15T23:59:59+00:00
Accession:  0001213900-24-069338
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma Q2 2024 EPS improves 86.8% to -$0.09; licensing deals worth up to $292M
--------------------------------------------------------------------------------

- EPS improved 86.8% YoY to -$0.09 in Q2 2024 from -$0.68; revenue surged to $117,142 from $6,109.
- Executed global licensing agreements for Vitargus (up to $187M) and oncology products (up to $105M) totaling potential $292M.
- Received $116,000 cash milestone in June 2024 from Vitargus licensing.
- Shareholders' equity stood at $7.8M as of June 30, 2024.
- Obtained US, Taiwanese, and Australian patents for Polygala extract for MDD and ADHD; FDA approved four INDs for oncology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024069338/0001213900-24-069338-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024069338/ea0211475-8k_abvc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-069338

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer